Non-animal testing market seen tripling to $29.4 billion by 2030

The global non-animal alternative testing market is projected to rise from $9.8 billion in 2021 to $29.4 billion by 2030, driven by stricter rules, ethical concerns and faster-moving biotech tools. The growth outlook spans pharmaceuticals, cosmetics, chemicals, food and diagnostics as regulators and companies shift away from animal testing.

Why it matters: - Non-animal testing is moving from a niche approach to a mainstream development tool across drug, cosmetics, chemicals, food and diagnostics. - The market’s projected expansion signals more spending on methods that can improve speed, ethics and predictive accuracy in safety testing. - Regulatory pressure and animal welfare concerns are reshaping how companies validate products before they reach consumers.

What happened: - Allied Market Research projected the global non-animal alternative testing market will grow from $9.8 billion in 2021 to $29.4 billion by 2030. - The market is expected to register a 13.5% compound annual growth rate from 2022 to 2030. - The report was released June 25, 2026. - The market is expanding across pharmaceutical, cosmetics, chemical, food and diagnostics industries.

The details: - Non-animal testing methods include cell culture technologies, high-throughput screening, molecular imaging, OMIC technologies, computational modeling and ex-vivo testing platforms. - Growth is being driven by increasing concerns about animal welfare and wider adoption of ethical research practices. - Regulatory agencies in multiple countries are tightening restrictions on animal testing and pushing industries toward alternatives. - Biotechnology, tissue engineering, organ-on-chip platforms, artificial intelligence and computational toxicology are improving accuracy and predictive performance. - Research and development spending is rising as demand increases for safer and more effective products. - Advanced in-vitro models, organoids, microphysiological systems and AI-driven predictive testing platforms are emerging as major opportunities. - Personalized medicine and precision healthcare are expected to add demand for innovative non-animal testing solutions. - Collaborations among biotechnology firms, pharmaceutical companies, research institutions and regulators are supporting innovation and commercial adoption. - Major companies named in the report include VITROCELL Systems GmbH, Evotec SE, Biovit, MB Research Laboratories, Emulate, TARA Biosystems, Bio-Rad Laboratories, Abbott, Hurel Corporation and TissUse GmbH. - The report segments the market by technology, method and end user. - Technology categories include cell culture, high throughput screening, molecular imaging and OMIC technologies. - Method categories include cellular assays, biochemical assays, in-silico models and ex-vivo methods. - End users include the pharmaceutical industry, cosmetics and household products, diagnostics, the chemical industry and the food industry. - North America held the largest market share, supported by major biotech and pharma companies, strong research infrastructure and favorable regulatory initiatives. - Asia-Pacific is expected to post the fastest growth over the forecast period. - The report says Asia-Pacific growth will be driven by expanding pharmaceutical research, higher healthcare investment and growing awareness of ethical testing. - The report covers North America, Europe, Asia-Pacific and LAMEA. - The report also says it analyzes market segments, trends, estimations, dynamics, drivers, restraints, opportunities, Porter’s five forces, regional revenue contribution and player positioning. - A sample report is available here. - A purchase enquiry page is available here.

Between the lines: - The forecast reflects a broader shift toward testing systems that promise faster iteration, lower ethical risk and more human-relevant results. - The strongest near-term growth appears tied to platforms that combine biology and computation, especially organ-on-chip and AI-enabled models. - North America’s lead suggests the market is still anchored by established research ecosystems, while Asia-Pacific looks positioned to gain share as investment accelerates.

What's next: - Regulatory scrutiny around animal testing is expected to intensify, which should keep demand for alternative methods rising. - Innovations in organ-on-chip technologies, AI-enabled predictive models and advanced cell-based assays are likely to shape product testing and drug development over the next decade. - Companies in the field are expected to keep focusing on technological innovation, strategic partnerships and product development to strengthen their positions.

The bottom line: - Non-animal testing is becoming a larger, better-funded market as regulators, researchers and industry players push for more ethical and scientifically advanced testing methods.